A newly identified blood marker tracks hidden disease progression in multiple sclerosis patients, offering clinicians a precise tool to measure worsening symptoms before clinical exams reveal changes. According to research published in Nature Medicine, researchers tracked neurofilament light chain (NfL) levels in the blood to monitor axonal damage in the central nervous system.
Tracking Neurofilament Light Chain in Multiple Sclerosis
Neurofilament light chain is a structural protein found inside nerve cells. When neurons sustain damage, NfL leaks into the cerebrospinal fluid and eventually enters the bloodstream. According to the National Multiple Sclerosis Society, elevated serum NfL concentrations strongly correlate with ongoing neurodegeneration and brain volume loss in people living with multiple sclerosis.
Clinicians often struggle to detect subtle disease progression during standard neurological exams, such as the Expanded Disability Status Scale. Blood-based NfL testing bridges this diagnostic gap. According to a study led by the National Institutes of Health, serial measurements of serum NfL help physicians identify subclinical disease activity in patients who report no new physical symptoms.
Comparing Traditional MRI Scans With Blood Biomarkers
Magnetic resonance imaging remains the standard method for visualizing multiple sclerosis lesions. However, MRI scans are costly, time-consuming, and fail to capture microscopic axonal injury occurring outside visible lesions. Blood markers provide a complementary approach that quantifies ongoing neurodegeneration without requiring frequent neuroimaging.
| Monitoring Method | Primary Function | Limitations |
|---|---|---|
| Serum NfL Blood Test | Quantifies active axonal damage via protein release | Nonspecific to MS alone; elevated in other neurological conditions |
| Brain MRI Scan | Visualizes focal demyelination and active lesions | High cost, limited availability, misses diffuse microscopic damage |
| Clinical Exam (EDSS) | Assesses physical disability and functional impairment | Subjective, insensitive to early or subclinical progression |
While MRI excels at showing macroscopic structural changes, serum NfL reflects real-time cellular injury. According to data from the Johns Hopkins Medicine multiple sclerosis center, combining annual MRI scans with periodic blood biomarker analysis improves a neurologist’s ability to evaluate whether a current disease-modifying therapy is successfully halting neurodegeneration.
Clinical Implications for Treatment Adjustments
Detecting hidden progression allows healthcare providers to modify treatment plans before irreversible neurological disability occurs. According to clinical guidelines discussed by the American Academy of Neurology, persistently high serum NfL levels despite treatment indicate that a patient may benefit from switching to a higher-efficacy disease-modifying therapy.
Researchers continue to standardize assay techniques so that clinicians everywhere can interpret blood NfL values consistently. As commercial laboratories validate these assays for routine clinical use, blood markers will likely become a standard component of regular multiple sclerosis management protocols.
Keep reading